An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.

Official Title

A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumours


The purpose of this study is to evaluate the safety and tumour-shrinking ability of experimental medication BMS-986156, when given by itself or in combination with nivolumab in patients with solid cancers that are advanced or cancers that have spread.

Trial Description

Primary Outcome:

  • Safety of BMS-986156 based on number of incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation and deaths in addition to clinical laboratory test abnormalities
Secondary Outcome:
  • Objective response rate (ORR)
  • Progression free survival rate (PFSR)
  • Duration of response
  • Maximum observed concentration (Cmax) of BMS-986156
  • Time of maximum observed concentration (Tmax) of BMS-986156
  • Area under the concentration-time curve in one dosing interval (AUC [TAU]) of BMS-986156
  • Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T) of BMS-986156
  • Anti-drug antibody (ADA) response to BMS-986156
  • Anti-drug antibody response to BMS-986156 and Nivolumab

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society